Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules for adults with tardive dyskinesia (TD) Home Logo

Tardive dyskinesia assessment and diagnosis

Make screening a part of your routine for all patients on antipsychotics

2020 American Psychiatric Association guidelines recommend1:

  1. 1

    Screening for TD before starting or changing patients’ dopamine receptor blocking agent (DRBA) treatment

  2. 2

    Monitoring for signs of TD at each visit

  3. 3

    Conducting a structured TD assessment every 6 to 12 months, depending on patient’s risk, and if new or worsening movements are detected at any visit

Review full APA guidelines

The involuntary and uncontrollable movements from TD may
not only impact your patients physically, but also emotionally2

When assessing the signs of tardive dyskinesia, ask about how it is affecting their everyday lives.

ASK ABOUT TD IMPACT

Tardive dyskinesia (TD) doesn’t just present in the face and mouth—involuntary movements may impact upper and lower limbs, the neck, and trunk3,4

UPPER LIMBS

Involuntary upper limbs movement, video

Asymmetrical movements, swaying, “piano fingers,” grabbing of clothing3,4

LOWER LIMBS

Involuntary lower limbs movement, video

Splayed or hyperextended toes, gripping, ankle twisting3,4

TORSO

Involuntary torso movement, video

Hyperextension, shifting, rocking3,4

TONGUE

Involuntary tongue movement, video

“Bonbon” sign, protrusion, darting3,4

EYES

Involuntary eyes movement, video

Excessive blinking and squinting3,4

LIPS

Involuntary lips movement, video

Smacking, puckering, pursing3,4

JAW

Involuntary jaw movement, video

Biting, clenching, lateral movements, chewing3,4

Actor portrayals

Take the TD Challenge: Assessment and diagnosis

Can you differentiate tardive dyskinesia from drug-induced parkinsonism and other acute drug-induced movement disorders?
Put your knowledge to the test.

START TD CHALLENGE

EXPERT PERSPECTIVES:

Tardive dyskinesia (TD) is clinically distinct

Dr. Laxman Bahroo, from Georgetown University’s Neurology Department, discusses the clinical distinctions between TD and acute drug-induced movement disorders and what to look for.

Tardive dyskinesia is clinically distinct, video

EXPERT PERSPECTIVES:

Tardive dyskinesia (TD) is clinically distinct

Dr. Laxman Bahroo, from Georgetown University’s Neurology Department, discusses the clinical distinctions between TD and acute drug-induced movement disorders and what to look for.

REFERENCES:

  1. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing, 2020.
  2. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303-3312.
  3. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised 1976. Rockville, MD: National Institute of Mental Health; 1976.
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
  5. Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
  6. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75.
  7. Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2):19cs12983.

REVIEW EFFICACY IN TD

Explore how INGREZZA® (valbenazine) capsules reduced TD severity in both short- and long-term studies of adult patients with TD

VISIT EFFICACY IN TD

TREAT FIRST LINE WITH VMAT2 INHIBITORS

VMAT2 inhibitors, like INGREZZA, are recommended as first-line treatment for TD1,6,7

VISIT TD GUIDELINES

SEE REAL-WORLD RESULTS
WITH INGREZZA

View videos of real-world patients with TD treated with INGREZZA

WATCH CASE VIDEOS

REFERENCES:

  1. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing, 2020.
  2. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303-3312.
  3. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised 1976. Rockville, MD: National Institute of Mental Health; 1976.
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
  5. Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
  6. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75.
  7. Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2):19cs12983.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.